+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sarcoidosis Therapeutics Market 2024-2028

  • PDF Icon

    Report

  • 158 Pages
  • December 2023
  • Region: Global
  • TechNavio
  • ID: 5561224
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The sarcoidosis therapeutics market is forecasted to grow by USD 72.82 mn during 2023-2028, accelerating at a CAGR of 4.94% during the forecast period. The report on the sarcoidosis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising awareness about sarcoidosis, special drug designations related to sarcoidosis therapeutics, and increasing funding for research on sarcoidosis.

The sarcoidosis therapeutics market is segmented as below:

By Product

  • Corticosteroids
  • Immunosuppressants and others

By Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the novel drug pipeline for sarcoidosis as one of the prime reasons driving the sarcoidosis therapeutics market growth during the next few years. Also, the development of biosimilars for immunosuppressants and personalized medicine for sarcoidosis will lead to sizable demand in the market.

The report on the sarcoidosis therapeutics market covers the following areas:

  • Sarcoidosis therapeutics market sizing
  • Sarcoidosis therapeutics market forecast
  • Sarcoidosis therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading sarcoidosis therapeutics market vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Anant Pharmaceuticals Pvt. Ltd., Atom Pharma, aTyr Pharma Inc., Fresenius SE and Co. KGaA, Halozyme Therapeutics Inc., Horizon Therapeutics Plc, Jubilant Pharmova Ltd., Kyorin Pharmaceutical Co. Ltd., Mallinckrodt Plc, Novartis AG, OrphAI Therapeutics, Pfizer Inc., Prometheus Laboratories, RELIEF THERAPEUTICS Holding SA, SarcoMedUSA Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Xentria Inc.. Also, the sarcoidosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global sarcoidosis therapeutics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global sarcoidosis therapeutics market 2018 - 2022 ($ million)
4.2 Product Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
4.3 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Product
6.1 Market segments
Exhibit 30: Chart on Product - Market share 2023-2028 (%)
Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Corticosteroids - Market size and forecast 2023-2028
Exhibit 34: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
6.4 Immunosuppressants and others - Market size and forecast 2023-2028
Exhibit 38: Chart on Immunosuppressants and others - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Immunosuppressants and others - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Immunosuppressants and others - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Immunosuppressants and others - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Product
Exhibit 42: Market opportunity by Product ($ million)
Exhibit 43: Data Table on Market opportunity by Product ($ million)
7 Market Segmentation by Distribution Channel
7.1 Market segments
Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
7.2 Comparison by Distribution Channel
Exhibit 46: Chart on Comparison by Distribution Channel
Exhibit 47: Data Table on Comparison by Distribution Channel
7.3 Hospital pharmacy - Market size and forecast 2023-2028
Exhibit 48: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 49: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 50: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
7.4 Retail pharmacy - Market size and forecast 2023-2028
Exhibit 52: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
7.5 Online pharmacy - Market size and forecast 2023-2028
Exhibit 56: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 60: Market opportunity by Distribution Channel ($ million)
Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 China - Market size and forecast 2023-2028
Exhibit 87: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on China - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 Canada - Market size and forecast 2023-2028
Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.11 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ million)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 111: AbbVie Inc. - Overview
Exhibit 112: AbbVie Inc. - Product/Service
Exhibit 113: AbbVie Inc. - Key news
Exhibit 114: AbbVie Inc. - Key offerings
12.4 Amneal Pharmaceuticals Inc.
Exhibit 115: Amneal Pharmaceuticals Inc. - Overview
Exhibit 116: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 117: Amneal Pharmaceuticals Inc. - Key news
Exhibit 118: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 119: Amneal Pharmaceuticals Inc. - Segment focus
12.5 Anant Pharmaceuticals Pvt. Ltd.
Exhibit 120: Anant Pharmaceuticals Pvt. Ltd. - Overview
Exhibit 121: Anant Pharmaceuticals Pvt. Ltd. - Product/Service
Exhibit 122: Anant Pharmaceuticals Pvt. Ltd. - Key offerings
12.6 aTyr Pharma Inc.
Exhibit 123: aTyr Pharma Inc. - Overview
Exhibit 124: aTyr Pharma Inc. - Product/Service
Exhibit 125: aTyr Pharma Inc. - Key offerings
12.7 Fresenius SE and Co. KGaA
Exhibit 126: Fresenius SE and Co. KGaA - Overview
Exhibit 127: Fresenius SE and Co. KGaA - Business segments
Exhibit 128: Fresenius SE and Co. KGaA - Key news
Exhibit 129: Fresenius SE and Co. KGaA - Key offerings
Exhibit 130: Fresenius SE and Co. KGaA - Segment focus
12.8 Halozyme Therapeutics Inc.
Exhibit 131: Halozyme Therapeutics Inc. - Overview
Exhibit 132: Halozyme Therapeutics Inc. - Product/Service
Exhibit 133: Halozyme Therapeutics Inc. - Key offerings
12.9 Horizon Therapeutics Plc
Exhibit 134: Horizon Therapeutics Plc - Overview
Exhibit 135: Horizon Therapeutics Plc - Business segments
Exhibit 136: Horizon Therapeutics Plc - Key news
Exhibit 137: Horizon Therapeutics Plc - Key offerings
Exhibit 138: Horizon Therapeutics Plc - Segment focus
12.10 Mallinckrodt Plc
Exhibit 139: Mallinckrodt Plc - Overview
Exhibit 140: Mallinckrodt Plc - Business segments
Exhibit 141: Mallinckrodt Plc - Key offerings
Exhibit 142: Mallinckrodt Plc - Segment focus
12.11 Novartis AG
Exhibit 143: Novartis AG - Overview
Exhibit 144: Novartis AG - Business segments
Exhibit 145: Novartis AG - Key offerings
Exhibit 146: Novartis AG - Segment focus
12.12 Pfizer Inc.
Exhibit 147: Pfizer Inc. - Overview
Exhibit 148: Pfizer Inc. - Product/Service
Exhibit 149: Pfizer Inc. - Key news
Exhibit 150: Pfizer Inc. - Key offerings
12.13 Prometheus Laboratories
Exhibit 151: Prometheus Laboratories - Overview
Exhibit 152: Prometheus Laboratories - Product/Service
Exhibit 153: Prometheus Laboratories - Key offerings
12.14 RELIEF THERAPEUTICS Holding SA
Exhibit 154: RELIEF THERAPEUTICS Holding SA - Overview
Exhibit 155: RELIEF THERAPEUTICS Holding SA - Product/Service
Exhibit 156: RELIEF THERAPEUTICS Holding SA - Key offerings
12.15 Teva Pharmaceutical Industries Ltd.
Exhibit 157: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 158: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 159: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 160: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 161: Teva Pharmaceutical Industries Ltd. - Segment focus
12.16 Viatris Inc.
Exhibit 162: Viatris Inc. - Overview
Exhibit 163: Viatris Inc. - Business segments
Exhibit 164: Viatris Inc. - Key news
Exhibit 165: Viatris Inc. - Key offerings
Exhibit 166: Viatris Inc. - Segment focus
12.17 Xentria Inc.
Exhibit 167: Xentria Inc. - Overview
Exhibit 168: Xentria Inc. - Product/Service
Exhibit 169: Xentria Inc. - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 170: Inclusions checklist
Exhibit 171: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 172: Currency conversion rates for US$
13.4 Research methodology
Exhibit 173: Research methodology
Exhibit 174: Validation techniques employed for market sizing
Exhibit 175: Information sources
13.5 List of abbreviations
Exhibit 176: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Product
Exhibits 6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global sarcoidosis therapeutics market 2018 - 2022 ($ million)
Exhibits 19: Historic Market Size - Product Segment 2018 - 2022 ($ million)
Exhibits 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Product - Market share 2023-2028 (%)
Exhibits 31: Data Table on Product - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Product
Exhibits 33: Data Table on Comparison by Product
Exhibits 34: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibits 35: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibits 36: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Immunosuppressants and others - Market size and forecast 2023-2028 ($ million)
Exhibits 39: Data Table on Immunosuppressants and others - Market size and forecast 2023-2028 ($ million)
Exhibits 40: Chart on Immunosuppressants and others - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Immunosuppressants and others - Year-over-year growth 2023-2028 (%)
Exhibits 42: Market opportunity by Product ($ million)
Exhibits 43: Data Table on Market opportunity by Product ($ million)
Exhibits 44: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits 46: Chart on Comparison by Distribution Channel
Exhibits 47: Data Table on Comparison by Distribution Channel
Exhibits 48: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 49: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 50: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 51: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 52: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 53: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 54: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 57: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 58: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 60: Market opportunity by Distribution Channel ($ million)
Exhibits 61: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 65: Chart on Geographic comparison
Exhibits 66: Data Table on Geographic comparison
Exhibits 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits 88: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits 89: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits 96: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits 97: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on Canada - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 103: Market opportunity By Geographical Landscape ($ million)
Exhibits 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 105: Impact of drivers and challenges in 2023 and 2028
Exhibits 106: Overview on Criticality of inputs and Factors of differentiation
Exhibits 107: Overview on factors of disruption
Exhibits 108: Impact of key risks on business
Exhibits 109: Vendors covered
Exhibits 110: Matrix on vendor position and classification
Exhibits 111: AbbVie Inc. - Overview
Exhibits 112: AbbVie Inc. - Product/Service
Exhibits 113: AbbVie Inc. - Key news
Exhibits 114: AbbVie Inc. - Key offerings
Exhibits 115: Amneal Pharmaceuticals Inc. - Overview
Exhibits 116: Amneal Pharmaceuticals Inc. - Business segments
Exhibits 117: Amneal Pharmaceuticals Inc. - Key news
Exhibits 118: Amneal Pharmaceuticals Inc. - Key offerings
Exhibits 119: Amneal Pharmaceuticals Inc. - Segment focus
Exhibits 120: Anant Pharmaceuticals Pvt. Ltd. - Overview
Exhibits 121: Anant Pharmaceuticals Pvt. Ltd. - Product/Service
Exhibits 122: Anant Pharmaceuticals Pvt. Ltd. - Key offerings
Exhibits 123: aTyr Pharma Inc. - Overview
Exhibits 124: aTyr Pharma Inc. - Product/Service
Exhibits 125: aTyr Pharma Inc. - Key offerings
Exhibits 126: Fresenius SE and Co. KGaA - Overview
Exhibits 127: Fresenius SE and Co. KGaA - Business segments
Exhibits 128: Fresenius SE and Co. KGaA - Key news
Exhibits 129: Fresenius SE and Co. KGaA - Key offerings
Exhibits 130: Fresenius SE and Co. KGaA - Segment focus
Exhibits 131: Halozyme Therapeutics Inc. - Overview
Exhibits 132: Halozyme Therapeutics Inc. - Product/Service
Exhibits 133: Halozyme Therapeutics Inc. - Key offerings
Exhibits 134: Horizon Therapeutics Plc - Overview
Exhibits 135: Horizon Therapeutics Plc - Business segments
Exhibits 136: Horizon Therapeutics Plc - Key news
Exhibits 137: Horizon Therapeutics Plc - Key offerings
Exhibits 138: Horizon Therapeutics Plc - Segment focus
Exhibits 139: Mallinckrodt Plc - Overview
Exhibits 140: Mallinckrodt Plc - Business segments
Exhibits 141: Mallinckrodt Plc - Key offerings
Exhibits 142: Mallinckrodt Plc - Segment focus
Exhibits 143: Novartis AG - Overview
Exhibits 144: Novartis AG - Business segments
Exhibits 145: Novartis AG - Key offerings
Exhibits 146: Novartis AG - Segment focus
Exhibits 147: Pfizer Inc. - Overview
Exhibits 148: Pfizer Inc. - Product/Service
Exhibits 149: Pfizer Inc. - Key news
Exhibits 150: Pfizer Inc. - Key offerings
Exhibits 151: Prometheus Laboratories - Overview
Exhibits 152: Prometheus Laboratories - Product/Service
Exhibits 153: Prometheus Laboratories - Key offerings
Exhibits 154: RELIEF THERAPEUTICS Holding SA - Overview
Exhibits 155: RELIEF THERAPEUTICS Holding SA - Product/Service
Exhibits 156: RELIEF THERAPEUTICS Holding SA - Key offerings
Exhibits 157: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 158: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 159: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits 160: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 161: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 162: Viatris Inc. - Overview
Exhibits 163: Viatris Inc. - Business segments
Exhibits 164: Viatris Inc. - Key news
Exhibits 165: Viatris Inc. - Key offerings
Exhibits 166: Viatris Inc. - Segment focus
Exhibits 167: Xentria Inc. - Overview
Exhibits 168: Xentria Inc. - Product/Service
Exhibits 169: Xentria Inc. - Key offerings
Exhibits 170: Inclusions checklist
Exhibits 171: Exclusions checklist
Exhibits 172: Currency conversion rates for US$
Exhibits 173: Research methodology
Exhibits 174: Validation techniques employed for market sizing
Exhibits 175: Information sources
Exhibits 176: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global sarcoidosis therapeutics market: AbbVie Inc., Amneal Pharmaceuticals Inc., Anant Pharmaceuticals Pvt. Ltd., Atom Pharma, aTyr Pharma Inc., Fresenius SE and Co. KGaA, Halozyme Therapeutics Inc., Horizon Therapeutics Plc, Jubilant Pharmova Ltd., Kyorin Pharmaceutical Co. Ltd., Mallinckrodt Plc, Novartis AG, OrphAI Therapeutics, Pfizer Inc., Prometheus Laboratories, RELIEF THERAPEUTICS Holding SA, SarcoMedUSA Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Xentria Inc..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is novel drug pipeline for sarcoidosis.'

According to the report, one of the major drivers for this market is the rising awareness about sarcoidosis.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • Anant Pharmaceuticals Pvt. Ltd.
  • Atom Pharma
  • aTyr Pharma Inc.
  • Fresenius SE and Co. KGaA
  • Halozyme Therapeutics Inc.
  • Horizon Therapeutics Plc
  • Jubilant Pharmova Ltd.
  • Kyorin Pharmaceutical Co. Ltd.
  • Mallinckrodt Plc
  • Novartis AG
  • OrphAI Therapeutics
  • Pfizer Inc.
  • Prometheus Laboratories
  • RELIEF THERAPEUTICS Holding SA
  • SarcoMedUSA Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Xentria Inc.

Related Topics

Related Reports

Chronic Obstructive Pulmonary Disease Drugs Market 2024-2028 - Product Image

Chronic Obstructive Pulmonary Disease Drugs Market 2024-2028

  • Report
  • 168 Pages
  • Global
From
Nontuberculous Mycobacterial Infections Market 2024-2028 - Product Image

Nontuberculous Mycobacterial Infections Market 2024-2028

  • Report
  • 177 Pages
  • Global
From
Pulmonary Sarcoidosis - Pipeline Insight, 2024 - Product Image

Pulmonary Sarcoidosis - Pipeline Insight, 2024

  • Clinical Trials
  • 50 Pages
  • Global
From
Interstitial Lung Disease Global Market Report 2024 - Product Image

Interstitial Lung Disease Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Sarcoidosis - Pipeline Insight, 2024 - Product Image

Sarcoidosis - Pipeline Insight, 2024

  • Clinical Trials
  • 75 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.